Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in oncology and infectious disease with a current focus on breast cancer and COVID-19, announces that it will hold a webinar at 8 am Pacific Time on June 9, 2021 to release and discuss final data from its Phase 2 study of Endoxifen administered to breast cancer patients prior to surgery. The webinar will be attended by Dr. Steven Quay, CEO and President, Kyle Guse, CFO and General Counsel, and Dr. B. Heather Fraser, VP Clinical, Regulatory and CMC.

To register to join the complimentary ZOOM-based webinar event, please visit Tribe Public LLC at ATOS.TribePublic.com. Registered participants may email questions for Atossa’s management to Tribe Public prior to the event at research@tribepublic.com or share their questions via the ZOOM chat feature during the event. Tribe Public’s Managing Member, John F. Heerdink, Jr., will host the event and relay questions to management.

About Atossa Therapeutics

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in oncology and infectious diseases with a current focus on breast cancer and COVID-19. For more information, please visit www.atossatherapeutics.com.

About Tribe Public LLC

Tribe Public LLC is a San Francisco, CA-based organization that hosts complimentary worldwide webinar & meeting events in the U.S. Tribe's events focus on issues that the Tribe's members care about with an emphasis on hosting management teams and experts from publicly traded companies from all sectors & financial organizations that are seeking to increase awareness of their products, progress, and plans. Tribe members primarily include Institutions, Family Offices, Portfolio Managers, Registered Investment Advisors, Accredited Investors, Sell Side Analysts, and members of media. Tribe Members are encouraged to express their interest in speakers at the Tribe Public website via the Tribe's FREE "Wish List" process. Visit Tribe Public's Website http://www.tribepublic.com/ to join the Tribe and express your interests today.

Forward-Looking Statements

Forward-looking statements in this press release, which Atossa undertakes no obligation to update, are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with any variation between interim and final clinical results, actions and inactions by the FDA, the outcome or timing of regulatory approvals needed by Atossa including those needed to commence studies of AT-H201, AT-301 and Endoxifen, lower than anticipated rate of patient enrollment, estimated market size of drugs under development, the safety and efficacy of Atossa’s products, performance of clinical research organizations and investigators, obstacles resulting from proprietary rights held by others such as patent rights, whether reduction in Ki-67 or any other result from a neoadjuvant study is an approvable endpoint for oral Endoxifen, and other risks detailed from time to time in Atossa’s filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.

Company Contact: Atossa Therapeutics, Inc. Kyle Guse CFO and General Counsel Office: (866) 893-4927 kyle.guse@atossainc.com

Investor Relations Contact: Core IROffice: (516) 222-2560ir@atossainc.com

Source: Atossa Therapeutics, Inc.

Atossa Therapeutics (NASDAQ:ATOS)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Atossa Therapeutics Charts.
Atossa Therapeutics (NASDAQ:ATOS)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Atossa Therapeutics Charts.